Skip to content

Effect of mouthwash on the reduction of salivary SARS-CoV-2

Investigation of the effect of mouthwash on the reduction of salivary SARS-CoV-2 in patients with mild or asymptomatic COVID-19

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs051220107
Enrollment
90
Registered
2022-10-18
Start date
2022-11-07
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

1. Medicinal Mondamin X-9N group Put about 20 mL of Medicinal Mondamin X-9N in mouth just before each meal, wash mouth for about 20 to 30 seconds, and then spit it out. 2. A2Care Mouthwash group Put

Sponsors

Kutsuna Satoshi
Lead Sponsor
Onozuka Daisuke
Collaborator
Earth Corporation
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Person who is diagnosed with COVID-19 using nucleic acid amplification method (PCR method, LAMP method, etc.), antigen qualitative test, antigen quantitative test (2) Person who recuperates at an accommodation recuperation facility (a specific facility) in Osaka Prefecture, or takes home recuperation and directly followed up by the Department of Infection Control, Osaka University Hospital (3) Person with asymptomatic or mild severity classification in the medical guide for COVID-19 (version 8.0) at informed consent (4) Person who is scheduled to have the first day of mouthwash within 7 days from the symptom onset date (or the sample collection date for positive confirmation when asymptomatic or the onset date is not clear) (5) Aged 18 years or older at informed consent (6) Person who has written consent to participate in this study

Exclusion criteria

Exclusion criteria: (1) Person who plans to have the first day of mouthwash as the final day of recuperation (2) Person who has difficulty collecting saliva by him/herself (3) Person who received or is scheduled to receive remdesivir, molnupiravir, nilmatrelvir / ritnavir, sotrovimab, casilibimab / imdebimab after the onset of this COVID-19 (4) Person who received anti-IL-6 antibody (tocilizumab, etc.), JAK inhibitors (baricitinib, etc.), oral or injectable steroids within the past 2 weeks, or will be administered by the morning of the second day of mouthwash (Including administration for diseases other than COVID-19) (5) Person who participated in clinical trials of COVID-19 therapeutic agents since the onset of this COVID-19 (6) Person with pregnant or lactating (7) Person with a history of hypersensitivity to the ingredients of Medicinal Mondamin X-9N or A2Care Mouthwash (8) Person who cannot meet online with the investigator using a smart phone, personal computer, etc. (9) Person who is judged by the investigator to be inappropriate as research subjects for other reasons

Design outcomes

Primary

MeasureTime frame
Change in saliva SARS-CoV-2 volume at 2 hours after the first mouthwash from baseline

Secondary

MeasureTime frame
(1) Change in saliva SARS-CoV-2 volume at 30 minutes after the first mouthwash from baseline (2) Change in saliva SARS-CoV-2 volume just before the mouthwash at noon of Day 1 from baseline (3) Change in saliva SARS-CoV-2 volume just before the mouthwash at evening of Day 1 from baseline (4) Change in saliva SARS-CoV-2 volume just before the mouthwash at morning of Day 2 from baseline (5) Change in SpO2 at morning of Day 2 from baseline (6) Change in clinical condition scale at morning of Day 2 from baseline (7) Change in SpO2 at morning of Day 7 or final day of recuperation from baseline (8) Change in clinical condition scale at morning of Day 7 or final day of recuperation from baseline

Contacts

Public ContactSatoshi Kutsuna

Osaka University Hospital

kutsuna@hp-infect.med.osaka-u.ac.jp+81-6-6879-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026